HSPG2 and prostate carcinoma: Given that Perlecan has been shown to modulate the signaling of multiple growth factors including FGF2, FGF10 and VEGF, we asked if the reduction of prostate cancer cell growth in Perlecan siRNA treated cells was a result of decreased SHH signaling.